Original Research
Published on 17 Feb 2021
The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
in Thoracic Oncology
![The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer](https://www.frontiersin.org/files/myhome article library/619010/619010_Thumb_400.jpg)
- 4,382 views
- 18 citations